TYPE 1 DIABETES：Dysglycaemia definitions and progression to clinical type 1

type 1 diabetes   search google or type a url The presymptomatic phase of type 1 diabetes is marked by the presence of two or more islet autoantibodies, classified into normoglycaemia stage 1 and dysglycaemia stage 2.1–3 These stages guide the indication of therapies such as the anti-CD3 antibody, teplizumab, which is FDA approved for children aged 8 years or older with stage 2 type 1 diabetes. In the past decade, criteria for stage

diabetes type 1 The presymptomatic phase of type 1 diabetes is marked by the presence of two or more islet autoantibodies, classified into normoglycaemia stage 1 and dysglycaemia stage 2.1–3 These stages guide the indication of therapies such as the anti-CD3 antibody, teplizumab, which is FDA approved for children aged 8 years or older with stage 2 type 1 diabetes. In the past decade, criteria for stage

diabetes mellitus type 2 Type 2 diabetes mellitus T2DM, accounting for the majority of diabetes mellitus prevalence, is associated with an increased risk of cognition decline and deterioration of cognition function in diabetic patients. The sodium–glucose cotransporter 2 SGLT2, located in the renal proximal tubule, plays a role in urine glucose reabsorption. SGLT2 inhibitors SGLT2i, have shown potential